Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2011 Financial Results on Monday, November 14, 2011

NANJING, China, Oct. 31, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2011 on Monday, November 14, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Monday, November 14 at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:United States toll-free:+1.866.519.4004United States toll:

+1.718.354.1231China Domestic:

800.819.0121 China Domestic mobile:

400.620.8038 Hong Kong:

+852.2475.0994Please ask to be connected to Q3 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 21357022.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1.866.214.5335United States toll:

+1.718.354.1232The passcode for replay participants is 21357022. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit

Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:In the United States:Yehong Zhang

Cindy ZhengPresident

Brunswick GroupSimcere Pharmaceutical GroupTel: +1-212-333-3810Tel: +86-25-8556-6666 ext. 88In Beijing:In Hong Kong:Yue Yu

Joseph Lo Chi-LunBrunswick Group

Brunswick GroupTel: +86-10-5960-8600

Tel: +852-3512-5000  

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simceres Iremod Receives SFDA New Drug Approval
2. Simceres Branded Generic Formulation Biqi Passes EU-GMP Inspection
3. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
4. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
5. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
6. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
7. Simcere Announces Recent Progress of Qiangkes Registration
8. Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
11. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
Post Your Comments:
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... of non-traumatic limb amputations in the United States. Podiatrists are well aware that ... to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Center of Excellence (BHCOE) today announced that the organization has awarded Education and ... Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers that ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
(Date:12/1/2015)... Beverly Hills, CA (PRWEB) , ... December 01, ... ... honored by Modern Luxury’s Angeleno Magazine as a Modern Man for 2015. ... luxury lifestyle publisher in the United States. Established in 1994, Modern Luxury includes ...
Breaking Medicine News(10 mins):